Press Releases - Vertex Pharmaceuticals Newsroom
Dec 8, 2024 · BOSTON --(BUSINESS WIRE)--Oct. 10, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
Vertex Announces Results From Phase 2 Study of Suzetrigine for …
Dec 19, 2024 · Vertex plans to advance suzetrigine into pivotal development for painful LSR following discussions with regulators on the study design and regulatory package. The company will apply learnings from analysis of the full Phase 2 data set and post-hoc analyses to inform the Phase 3 study design.
Press Release - Vertex Pharmaceuticals Newsroom
Apr 10, 2024 · Under the terms of the merger agreement, Vertex will acquire Alpine for $65 per share in cash, for a total equity value of approximately $4.9 billion, or approximately $4.6 billion net of estimated cash acquired. A subsidiary of Vertex will commence a cash tender offer to purchase all outstanding shares of Alpine common stock.
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential …
Oct 18, 2024 · BOSTON--(BUSINESS WIRE)--Oct. 18, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American ...
Press Release - Vertex Pharmaceuticals Newsroom
Jan 30, 2024 · Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain – Treatment with VX-548 led to statistically significant improvement in pain compared to placebo as well as a clinically meaningful reduction in pain from baseline in both the abdominoplasty and bunionectomy randomized ...
Vertex Reports Third Quarter 2024 Financial Results
Sep 30, 2024 · BOSTON--(BUSINESS WIRE)--Nov. 4, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to …
Press Release - Vertex Pharmaceuticals Newsroom
Jun 23, 2023 · Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions – All six patients treated with VX-880 engrafted islet cells, produced endogenous insulin (C-peptide) and had improved glycemic control while reducing or eliminating insulin use –
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of ...
Sep 26, 2024 · BOSTON--(BUSINESS WIRE)--Sep. 26, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor (“vanza triple”) — the potential next-in-class triple combination medicine — will take place at ...
Press Release - Vertex Pharmaceuticals Newsroom
Apr 23, 2024 · TreeFrog and Vertex will collaborate to scale-up TreeFrog’s process to produce and amplify cells for Vertex’s T1D therapies. TreeFrog’s proprietary technology platform, C-Stem™, is designed to mimic the natural microenvironment, allowing cells to …
Press Release - Vertex Pharmaceuticals Newsroom
Jul 30, 2024 · Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain – FDA grants priority review and assigns a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025 –
- Some results have been removed